Key result
Clozapine use linked to fatal hypersensitivity myocarditis presenting as SCD at 6 weeks.
Case Report (n=1)
No
Clozapine can cause fatal hypersensitivity myocarditis, underscoring the potential utility of a 4-week monitoring protocol with troponin and CRP after drug initiation.
Answers are grounded in this paper and cite their sources.
Fatal clozapine myocarditis risk warrants early vigilance; leaves open whether troponin/CRP monitoring improves outcomes.
Hypersensitivity myocarditis is a rare but serious adverse effect of clozapine, a commonly used psychiatric drug. We report the case of sudden cardiac death from clozapine-induced hypersensitivity myocarditis diagnosed at autopsy. A 54-year-old Caucasian male on clozapine therapy for bipolar disorder presented with a sudden onset of shortness of breath. Laboratory studies were significant for elevated N-terminal prohormone of brain natriuretic peptide. During his hospital stay, the patient died of sudden cardiac arrest from ventricular tachycardia. The autopsy revealed hypersensitivity myocarditis, which usually occurs in the first 4 weeks after the initiation of clozapine. A 4-week monitoring protocol, including laboratory assessment of troponin and C-reactive protein, may assist in the early diagnosis of this potentially fatal condition.
No takes yet. Share an insight, caveat, or question.
Katta et al. (2016) conducted a case report in Clozapine-induced hypersensitivity myocarditis (n=1). Clozapine was evaluated. A 54-year-old male treated with clozapine for 6 weeks developed fatal hypersensitivity myocarditis presenting as sudden cardiac death, which was diagnosed at autopsy.
Synapse has enriched 10 related papers. Consider them for comparative context: